Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia
Authors' conclusion
Adolescents with classic 21OHD CAH had substantial reductions in adrenal androgens and androgen precursors after 14 days of oral crinecerfont administration. These results are consistent with a study of crinecerfont in adults with classic 21OHD CAH.
Study context
- Population
- Males and females aged 14 to 17 years with classic 21OHD congenital adrenal hyperplasia (CAH); median age 15 years, 88% Caucasian/White3 males · 5 females
- Participants
- 8 participants
- Outcome
- Change from baseline in circulating ACTH, 17OHP, androstenedione and testosterone
- Follow-up
- Day 14
Methodological details4 centres in the United States
- 4 centres in the United States
Main finding
As reported in the abstract
Median percent reduction from baseline
ACTH, median % change from baseline
−57%
17OHP, median % change from baseline
−69%
Androstenedione, median % change from baseline
−58%
Females with ≥50% reduction from baseline in testosterone
60%
3/5
Original publication
Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. Published 22 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →